Pan-RAS/MAPK pathway shutdown for cancer control
PrimaryErasca's central causal theory is that many cancers are sustained by aberrant signaling through the RAS/MAPK pathway, one of the most commonly mutated cancer signaling cascades. Therefore, a modality-agnostic precision oncology pipeline that inhibits the pathway at multiple nodes should suppress tumor growth in cancers driven by this cascade. Testable predictions include reduced MAPK pathway signaling biomarkers after treatment, tumor growth inhibition or regression in RAS/MAPK-driven models, and clinical antitumor activity in patients whose tumors carry relevant RAS/MAPK alterations.
Popperian evaluation
The core premise is credible: RAS/MAPK signaling is a well-established cancer driver, and KRAS G12D is reported here as present in about 45% of pancreatic ductal adenocarcinoma. The weaker link is dependence. A tumor can carry a pathway alteration and still evade single-node inhibition through feedback, bypass signaling, or heterogeneity. The theory is biologically grounded, but the word "many" hides a hard selection problem.
Supporting evidence: The theory states that many cancers are sustained by aberrant RAS/MAPK signaling.; The cited 2023 ACS Medicinal Chemistry Letters paper says KRAS G12D occurs in approximately 45% of pancreatic ductal adenocarcinoma cases.; ERAS-5024 inhibited ERK1/2 phosphorylation in AsPC-1 pancreatic cancer cells with single-digit nanomolar potency.
Counter evidence: The evidence supplied supports KRAS G12D inhibition specifically, not shutdown of the whole pathway across multiple cancer types.; The assumption that tumors with relevant RAS/MAPK alterations remain pathway-dependent is marked medium confidence.
The theory explains the biomarker and model data: inhibit KRAS G12D, ERK1/2 phosphorylation falls, proliferation drops, and tumors regress in vivo. That is a clean causal chain for this compound in these models. It explains less about clinical response, durability, resistance, or whether a modality-agnostic multi-node pipeline beats narrower alternatives such as mutant-specific KRAS inhibition alone.
Supporting evidence: ERAS-5024 reduced ERK1/2 phosphorylation, matching the predicted drop in MAPK pathway signaling.; ERAS-5024 inhibited proliferation in three-dimensional Cell-Titer Glo assays in AsPC-1 PDAC cells.; ERAS-5024 caused tumor regression in in vivo efficacy studies.
Counter evidence: No clinical antitumor activity data are provided for patients with RAS/MAPK alterations.; The supplied evidence does not compare multi-node pathway inhibition against alternative explanations or treatment strategies.; The clinical prediction remains medium confidence, with no supporting publication listed.
This theory is easy to put in front of a hard test. It predicts lower ERK1/2 phosphorylation after treatment, growth inhibition or regression in RAS/MAPK-driven models, and clinical antitumor activity in alteration-positive patients. If pathway biomarkers stay high, tumors keep growing, or selected patients fail to respond despite target engagement, the theory takes a direct hit.
Supporting evidence: The theory predicts reduced MAPK pathway signaling biomarkers such as ERK1/2 phosphorylation.; The theory predicts tumor growth inhibition or regression in RAS/MAPK-driven preclinical models.; The theory predicts clinical antitumor activity in patients whose tumors carry relevant RAS/MAPK alterations.
Counter evidence: The phrase "relevant RAS/MAPK alterations" needs strict molecular criteria to prevent moving the goalposts after negative results.; A broad pipeline claim could survive failure of one inhibitor unless the theory defines which nodes, tumor genotypes, doses, and biomarker thresholds count as a real test.
Reasoning tree
Public endorsements
The public record here shows ARCH Venture Partners co-led Erasca's April 27, 2020 Series B financing, which supports the company financially, but it does not include any attributable statement from ARCH about Erasca's pan-RAS/MAPK theory. With no quote, interview, or publication tying ARCH directly to that mechanism claim, silence is the accurate call.
Evidence publication IDs: 319ac435-0e0e-4d90-b040-3c46b48d1299
The record shows Erasca publicly describing its approach as a singular focus on shutting down the RAS/MAPK pathway, and it names Dr. Yaron in executive context, but it does not attribute that theory to her in a direct statement, interview, or quote. On this evidence, she is publicly associated with the company, not publicly on record endorsing or disputing the theory herself.
Evidence publication IDs: 31c52098-4ecd-48eb-8aa9-60859084b910
The public material points in the same direction, but it does not state the full pan-RAS/MAPK theory outright. In the June 11, 2019 site snapshot, Erasca says its OPRA platform looks for strategies that "shut down key cancer pathways" with single-agent and combination approaches. The January 25, 2021 snapshot also says the company is driven by advances in drugging biological drivers of cancer and is not tied to one form of drug or one singular treatment approach. That is a public mention of a multi-approach pathway-control idea, not a direct founder-level endorsement of the specific claim that broad RAS/MAPK inhibition across multiple nodes will control RAS/MAPK-driven cancers.
Evidence publication IDs: 520a126c-8f8e-452c-8be1-af0ba1f4d52f, a7fd675f-fd35-48a2-a655-c5ae7cf748a8
Lim publicly backs the core idea that RAS-driven tumors should be treated by targeted pathway intervention. His statement supporting a Merck combination "to advance this promising investigational combination in RAS-driven cancers" is an endorsement of the company’s RAS-focused therapeutic theory, even though the quote does not spell out the full pan-RAS/MAPK, multi-node mechanism.